By Kathryn Calkins
Staff Writer

Companies take a variety of measures to prevent or catch data manipulation, but the key is simple: repeat experiments at separate sites and with separate investigators. Isis Pharmaceuticals Inc.'s encounter with data manipulation by a researcher at partner Novartis demonstrated the value of following this basic tenet of science. Last week, the company was able to report having a large body of independent animal data to rely on as it moves forward with clinical trials of the compounds affected by the incident (see BioCentury Extra, March 17).